Troponin I1: A Protein Regulating Myocardial Function and Angiogenesis

Target Name: TNNI1

NCBI ID: G7135

TNNI1

Troponin I1: A Protein Regulating Myocardial Function and Angiogenesis

Troponin I1 (TNNI1) is a protein that is expressed in various tissues throughout the body, including muscle, heart, and blood vessels. It is a key regulator of the myocardial contractile cycle, which is the process by which the heart muscle relaxes and contracts to pump blood throughout the body.

TNNI1 is composed of two subunits, known as alpha- and beta-subunits. The alpha-subunit consists of 120 amino acids, while the beta-subunit consists of 118 amino acids. The alpha-subunit contains a single kinase domain, which is responsible for the catalytic activity of the protein. The beta-subunit contains a single regulatory domain, which is responsible for the regulation of the alpha-subunit.

TNNI1 is expressed in a variety of tissues and is involved in the regulation of many different physiological processes in the body. It is expressed in the heart, where it is involved in the regulation of cardiac contractility and heart rate. It is also expressed in the muscle, where it is involved in the regulation of muscle contractility.

TNNI1 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is thought to be important for the development and maintenance of cardiovascular disease.

TNNI1 is a potential drug target because of its involvement in the regulation of myocardial function and angiogenesis. Many studies have suggested that inhibiting the activity of TNNI1 may be a useful way to treat cardiovascular disease.

One way to inhibit the activity of TNNI1 is through the use of small interfering RNA (siRNA). SiRNA is a type of RNA that can be used to knockdown the expression of a specific gene, such as TNNI1. This is done by introducing a small interfering RNA into the cells, which acts to reduce the amount of TNNI1 that is produced.

Another way to inhibit the activity of TNNI1 is through the use of a drug called Troponin I1 inhibitor (TNNI1-I). This drug is designed to bind to the alpha-subunit of TNNI1 and prevent it from catalyzing the kinase reaction that is responsible for its activity. This is done by blocking the interaction between the alpha-subunit and the drug, which prevents it from activating the alpha-subunit and catalyzing the kinase reaction.

In conclusion, Troponin I1 (TNNI1) is a protein that is involved in the regulation of myocardial function and angiogenesis. It is a potential drug target because of its involvement in these processes, and there is ongoing research into the use of small interfering RNA and Troponin I1 inhibitor to inhibit its activity. Further studies are needed to fully understand the role of TNNI1 in the regulation of myocardial function and angiogenesis.

Protein Name: Troponin I1, Slow Skeletal Type

Functions: Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity

The "TNNI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNNI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets